Join Growin Stock Community!

Minerva neurosciences, inc.NERV.US Overview

US StockHealthcare
(No presentation for NERV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NERV AI Insights

NERV Overall Performance

NERV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NERV Recent Performance

-1.44%

Minerva neurosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NERV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NERV Key Information

NERV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NERV Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Price of NERV

NERV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NERV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.87
PB Ratio
2.68
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.87
PB Ratio
2.68
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NERV's latest earnings report released?

    The most recent financial report for Minerva neurosciences, inc. (NERV) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NERV's short-term business performance and financial health. For the latest updates on NERV's earnings releases, visit this page regularly.

  • How much cash does NERV have?

    At the end of the period, Minerva neurosciences, inc. (NERV) held Total Cash and Cash Equivalents of 12.39M, accounting for 0.44 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NERV's EPS continuing to grow?

    According to the past four quarterly reports, Minerva neurosciences, inc. (NERV)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NERV?

    Minerva neurosciences, inc. (NERV)'s Free Cash Flow (FCF) for the period is -2.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.